Status:
APPROVED_FOR_MARKETING
An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck
Lead Sponsor:
AstraZeneca
Conditions:
Non Small Cell Lung Cancer
Cancer of the Head and Neck
Eligibility:
All Genders
18-130 years
Brief Summary
The purpose of this study is to provide ZD1839 for those patients with locally advanced and/or metastatic non-operable non-small cell lung cancer (stage III or IV) or recurrent and/or metastatic squam...
Eligibility Criteria
Inclusion
- Have received at least one course of standard systemic chemotherapy or radiation therapy
- Are ineligible for chemotherapy or radiotherapy
- Are ineligible or not candidates for enrollment in available ZD1839 trials for NSCLC or squamous cell H\&NC
- Are, in the investigators opinion, not medically suitable for chemotherapy.
Exclusion
- Current eligibility (i.e., meeting the inclusion and exclusion criteria except signed informed consent) for any ZD1839 protocol available to the patient, or previous enrollment in a blinded ZD1839 protocol
- Patients from a blinded protocol may be considered for acceptance, with AstraZeneca's permission, only after trial completion and unblinding of all patients.
- Patients eligible for or previously enrolled in an open-label or unblinded ZD1839 clinical trial may be considered for acceptance with AstraZeneca's permission
- Incomplete healing from prior oncologic or other major surgery
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00684385
Last Update
March 14 2019
Active Locations (34)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Berlin, Germany, 10117
2
Research Site
Berlin, Germany, 13125
3
Research Site
Berlin, Germany, 13189
4
Research Site
Berlin, Germany, 14165